Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
This is a phase 2/3 open-label study to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) in subjects with IgAN.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sibeprenlimab 400 mg s.c. Q4weeks
Eligibility
Inclusion Criteria:
- Subjects who completed Trial 417-201-00007 or VIS649-201 without safety concerns and
who, in the opinion of the investigator, could potentially benefit from treatment with
sibeprenlimab.
- eGFR ≥ 20 mL/min/1.73 m2, calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula.
Exclusion Criteria:
- Subjects who have not completed participation in trials 417-201-00007 or VIS649-201.
- Subjects who, following enrollment in trials 417-201-00007 or VIS649-201 developed a
condition or characteristic that would have excluded them from participation in these
trials.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shiktj Dave
650-723-2240
I'm interested
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.